文献速递前列腺癌

ProtecT试验:局限期前列腺癌按实际治疗分析的十年死亡率、疾病进展与治疗相关副作用

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
PubMed 文献 · Eur Urol · 2019-11-24

基于ProtecT随机对照试验,比较主动监测、根治性前列腺切除术和放疗在局限期前列腺癌男性中的结局。按实际治疗分析显示,主动监测组前列腺癌死亡、转移和疾病进展更常见,但性功能和排尿功能副作用更少。

要点

  • 主动监测组前列腺癌死亡1.85%,手术组0.67%,放疗组0.73%。
  • 主动监测组转移5.6%,手术组2.4%,放疗组2.7%;疾病进展分别为20.35%、5.87%、6.62%。
  • 手术后6个月性功能障碍95%、尿失禁55%;放疗后6个月性功能障碍88%、肠道功能障碍5%。

核心结论

  • 按实际治疗分析,主动监测组疾病相关事件发生率高于根治性治疗组,且前列腺癌死亡证据更强。
  • 主动监测组患者报告的功能副作用(性功能和排尿功能)明显低于手术或放疗组。

研究设计与样本

  • 研究纳入1643名同意随机分组的局限期前列腺癌男性,另997名拒绝随机分组并选择治疗者组成选择队列。
  • 按实际接受的治疗进行分析,并使用倾向性评分校正已知预后因素,采用荟萃分析合并估计。

主要发现

  • 主动监测组前列腺癌死亡1.85%,手术组0.67%,放疗组0.73%;随机队列中差异与 chance 一致(p=0.08)。
  • 探索性分析(随机加选择队列)中,主动监测与根治性治疗组合并比较,前列腺癌死亡差异有统计学意义(p=0.003)。
  • 主动监测组转移5.6%,手术组2.4%,放疗组2.7%;疾病进展分别为20.35%、5.87%、6.62%。
  • 与主动监测相比,手术后6个月性功能障碍风险95%、尿失禁风险55%;放疗后6个月性功能障碍风险88%、肠道功能障碍风险5%。

关键数值与推荐

  • 主动监测组前列腺癌死亡1.85%,手术组0.67%,放疗组0.73%。
  • 主动监测组转移5.6%,手术组2.4%,放疗组2.7%。
  • 主动监测组疾病进展20.35%,手术组5.87%,放疗组6.62%。
  • 手术后6个月性功能障碍95%、尿失禁55%。
  • 放疗后6个月性功能障碍88%、肠道功能障碍5%。

临床怎么用

  • 临床咨询时应告知局限期前列腺癌患者:主动监测可减少性功能和排尿功能副作用,但疾病进展和转移风险高于根治性治疗。
  • 治疗决策需结合患者对肿瘤进展风险与功能副作用的权衡。

局限性

  • 按实际治疗分组比较存在潜在偏倚。
  • 长期随访期间所评估的干预措施可能已过时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. OBJECTIVE: To determine report outcomes according to treatment received in men in randomised and treatment choice cohorts. DESIGN, SETTING, AND PARTICIPANTS: This study focuses on secondary care. Men with clinically localised prostate cancer at one of nine UK centres were invited to participate in the treatment trial comparing AM, radical prostatectomy, and radiotherapy. INTERVENTION: Two cohorts included 1643 men who agreed to be randomised; 997 declined randomisation and chose treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Health-related quality of life impacts on urinary, bowel, and sexual function were assessed using patient-reported outcome measures. Analysis was carried out based on treatment received for each cohort and on pooled estimates using meta-analysis. Differences were estimated with adjustment for known prognostic factors using propensity scores. RESULTS AND LIMITATIONS: According to treatment received, more men receiving AM died of PCa (AM 1.85%, surgery 0.67%, radiotherapy 0.73%), whilst this difference remained consistent with chance in the randomised cohort (p=0.08); stronger evidence was found in the exploratory analyses (randomised plus choice cohort) when AM was compared with the combined radical treatment group (p=0.003). There was also strong evidence that metastasis (AM 5.6%, surgery 2.4%, radiotherapy 2.7%) and disease progression (AM 20.35%, surgery 5.87%, radiotherapy 6.62%) were more common in the AM group. Compared with AM, there were higher risks of sexual dysfunction (95% at 6mo) and urinary incontinence (55% at 6mo) after surgery, and of sexual dysfunction (88% at 6mo) and bowel dysfunction (5% at 6mo) after radiotherapy. The key limitations are the potential for bias when comparing groups defined by treatment received and outdating of the interventions being evaluated during the lengthy follow-up required in trials of screen-detected PCa. CONCLUSIONS: Analyses according to treatment received showed increased rates of disease-related events and lower rates of patient-reported harms in men managed by AM compared with men managed by radical treatment, and stronger evidence of greater PCa mortality in the AM group. PATIENT SUMMARY: More than 90 out of every 100 men with localised prostate cancer do not die of prostate cancer within 10yr, irrespective of whether treatment is by means of monitoring, surgery, or radiotherapy. Side effects on sexual and bladder function are much better after active monitoring, but the risks of spreading of prostate cancer are more common.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Neal DE, Metcalfe C, Donovan JL, et al. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. Eur Urol. 2019. PMID: 31771797. doi:10.1016/j.eururo.2019.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。